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Previously, the field of tumor immunology has relied on
T cell receptor (TCR) transgenic mice and model tumor
antigens to study the T cell:tumor cell interaction. How-
ever, these models have limitations. Namely, they do not
reflect the natural affinity, repertoire, or precursor
frequency of tumor antigen-specific T cells. Using a novel
TCR affinity tool, the Nur77GFP mouse, we have charac-
terized the signal strength and phenotype of naturally
occurring tumor antigen-specific CD8 T cells. Our data
suggest that the co-expression of Nur77GFP and PD-1
identifies a population of polyclonal CD8+ tumor infiltrat-
ing lymphocytes (TIL) that are tumor antigen-specific.
This population produces more IFN-g in situ and upon
re-stimulation with syngeneic but not allogeneic tumor
cells. In addition, treatment of tumor bearing mice with
an OX40 agonist mAb doubled the frequency of tumor
reactive T cells receiving strong TCR signals as compared
to the control (~two-fold increase in CD8+Nur77GFPhi
p=.0027). PD-1, PDL-1, or CTLA4 blockade also had a
modest influence on the frequency of CD8+Nur77GFPhi
TIL but this was not as significant as anti-OX40 mAb. To
further understand the anti-tumor immune response, CD8
+Nur77GFPhi and Nur77GFPlo TIL were sorted and the
TCRb CDR3 region was sequenced. We observed clonal
expansions of unique Vb sequences exclusively found in
the TIL population after anti-OX40 immunotherapy.
Unexpectedly, the CD8+ Nur77GFPlo population sorted
from mice treated with the anti-OX40 mAb contained
very similar Vb sequences and together these represented
more than 30% of the TCR repertoire. This suggests that
both weak and strong tumor antigens drive TIL expansion
after anti-OX40 mAb immunotherapy. Importantly, these
repertoire changes were not observed with the control
antibody in TIL nor in the spleens of OX40 agonist treated
mice. OX40 agonist therapy also increased the frequency
of PD-1+ TIL suggesting that targeting this inhibitory
molecule in combination with OX40 might improve
tumor rejection. In fact, when established tumors
(~50mm2) were treated with a combination of anti-OX40
and anti-PDL-1, significant tumor regression and disease
free survival was observed in multiple tumor models
(C57Bl/6:MCA205 50% survival p < 0.0001, Balb/c:CT26
30% survival p = 0.0105). Tumor rejection corresponded
to an increase in the circulation of CD44hi, proliferating,
CD8 T cells that was observed only in the combination
therapy group as compared to either single agent alone.
Therefore, we propose that one mechanism of OX40
agonist immunotherapy is via the priming and expansion
of low and high affinity tumor antigen specific CD8 T cells.
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